Zealand Pharma to participate in SVB Leerink 9th Annual Global Healthcare Conference

Rhea-AI Summary

Zealand Pharma A/S (Nasdaq: ZEAL) announced its participation in the SVB Leerink 9th Annual Global Healthcare Conference on February 24, 2021. Members of Zealand's senior management will present virtually at 8:00 a.m. ET. A live webcast can be accessed on the company’s website, with a replay available after the event. Zealand focuses on developing peptide-based medicines and is advancing multiple drug candidates, including one under review for regulatory approval in the U.S.

Press Release – No. 7 / 2021

Copenhagen, DK and Boston, MA, February 9, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the SVB Leerink 9^th Annual Global Healthcare Conference.

SVB Leerink Global Healthcare Conference
Date: Wednesday, February 24, 2021
Presentation: 8:00 a.m. ET/ 2:00 p.m. CET

A live webcast of the event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go^®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.  

For further information, please contact: 

Zealand Pharma Investor Relations
Maeve Conneighton
Argot Partners
investors@zealandpharma.com

Zealand Pharma Media Relations 
David Rosen 
Argot Partners
media@zealandpharma.com

FAQ

When is Zealand Pharma's presentation at the SVB Leerink Global Healthcare Conference?

Zealand Pharma's presentation is scheduled for February 24, 2021, at 8:00 a.m. ET.

How can I view the SVB Leerink conference presentation by Zealand Pharma?

The presentation can be viewed via a live webcast on Zealand Pharma's 'Events & Presentations' page.

What is the focus of Zealand Pharma's business?

Zealand Pharma focuses on the discovery, development, and commercialization of innovative peptide-based medicines.

What are some recent developments from Zealand Pharma?

Zealand has more than 10 drug candidates in clinical development, with one candidate currently under regulatory review in the U.S.

Where is Zealand Pharma headquartered?

Zealand Pharma is headquartered in Copenhagen, Denmark.